Quantcast

Latest Endocrine system Stories

2014-06-14 12:20:58

During the 1-year program, patients showed statistically significant reductions in blood glucose levels, increased belief in their ability to self-manage their diabetes and improved perceptions of support, while the community showed statistically significant increases in diabetes awareness SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- The American Academy of Family Physicians Foundation announced today that the Cities for Life program, supported by Sanofi US, helped decrease blood glucose...

2014-06-14 12:20:53

SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Data from a new phase 3 study demonstrated that once-daily Victoza(R) (liraglutide [rDNA origin] injection) provided greater glycaemic control versus placebo with no worsening of renal function in adults with type 2 diabetes and moderate renal impairment.[1],[2] The data were presented today at the 74th Annual Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, CA. Renal impairment is one of the more...

2014-06-14 12:20:50

Data Presented at ADA Scientific Sessions Suggest DRI May Enable More Timely and Focused Risk Assessment and Intervention in At-risk Patients SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced the presentation of data demonstrating the utility of the company's...

2014-06-14 12:20:48

CSO Dr. Peter Daddona to Share Data on Use of ZP-Glucagon Product Candidate in Healthy Volunteers FREMONT, Calif., June 14, 2014 /PRNewswire/ -- Zosano Pharma, Inc., a privately held biopharmaceutical company developing products based on its novel transdermal delivery technology, announced that Peter Daddona, Ph.D., Chief Scientific Officer and Executive Vice President, Research & Development, will present data today on its ZP-Glucagon product candidate at the 74(th) American...

2014-06-14 12:20:45

Once-Weekly Dulaglutide 1.5 mg Also Demonstrates Weight Loss, Low Rates of Hypoglycemia in AWARD-6 Trial SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today released detailed results from dulaglutide's sixth AWARD trial, showing that once-weekly dulaglutide 1.5 mg was non-inferior to once-daily liraglutide 1.8 mg. The non-inferiority study demonstrated similar reductions in average blood sugar levels (HbA1c) across both arms.(1) The head-to-head study compared...

2014-06-14 12:20:43

Data presented at the 74th American Diabetes Association Scientific Sessions® expand body of evidence for the mechanism of action of basal insulin peglispro in healthy human subjects SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data regarding the mechanism of action of basal insulin peglispro (BIL). When BIL and insulin glargine were each administered to achieve complete suppression of glucose production, which principally comes from the...

2014-06-14 12:20:40

Companies present comprehensive data for LY2963016, investigational new insulin glargine product SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- For the first time today, Eli Lilly and Company (NYSE:LLY) and Boehringer Ingelheim Pharmaceuticals Inc. presented data showing that LY2963016, the alliance's investigational new insulin glargine product, has a similar safety and efficacy profile to currently marketed insulin glargine (Lantus(®)).(1,2,3,4,5,6) Results from these Phase I and Phase III...

2014-06-14 12:20:36

SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- New Phase 3a findings show IDegLira, the investigational once-daily single injection combination of insulin degludec and liraglutide, for the treatment of people with type 2 diabetes, maintained its glucose-lowering effect and confirmed safety evaluations for up to one year.[1] Findings from the 26-week extension of the DUAL(TM) I clinical trial programme were presented today at the 74th Annual Scientific Sessions of the American...

2014-06-14 12:20:29

Data also showed liraglutide 3 mg improved blood glucose control compared to placebo at 56 weeks SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Today, primary results from SCALE(TM) Diabetes, a phase 3a clinical trial of liraglutide 3 mg, an investigational once-daily glucagon-like peptide-1 (GLP-1) analogue for chronic weight management, were presented for the first time at the 74th Annual Scientific Sessions of the American Diabetes Association (ADA) in San Francisco,...

2014-06-13 23:08:15

Attorneys at The Onder Law Firm investigating Androgel lawsuits offer free case review for individuals whose spouse, father, or another family member died of a heart attack while taking Androgel testosterone for possible inclusion in Illinois multi-district litigation. St. Louis, MO (PRWEB) June 13, 2014 Androgel lawsuits for heart attack and stroke were consolidated in the Northern District of Illinois, Chicago court last week (In Re AndroGel Products Liability Litigation, MDL No. 2545,...


Latest Endocrine system Reference Libraries

Technophobia
2013-12-24 11:45:54

Technophobia, from Greek techne, meaning art, skill, or craft, and phobos, meaning fear, is the fear or the dislike of advanced technology or complex devices, particularly computers. Although there are a number of interpretations of technophobia, they appear to become more complex as technology continues to evolve. The term is usually used in the sense of irrational fear, but others contend that their fears are justified. It is related to cyber phobia and it is the opposite of technophilia....

Pituitary gland
2013-04-30 10:34:49

The pituitary gland, also called the hypophysis, is an endocrine organ found within a small, bony cavity at the base of the brain. Its primary function is to secrete hormones that regulate homeostasis. More specifically, the pituitary gland is a glandular structure about the size of a pea. It is located below the brain and above the nasal cavity in a protected pocket called the sella turcica, which is within the sphenoid bone. It connects to the hypothalamus via a neck-like structure...

Pineal Gland
2013-04-30 10:31:18

The pineal gland, also called the epiphysis cerebri, is an endocrine organ located in the brain. Its primary function is to regulate the sleep cycle and influence sexual development. It is a reddish-gray glandular structure that forms the roof of the third ventricle in the brain, between the two lateral ventricles, tucked in a groove near the thalamic bodies. Its body is relatively the size of a grain of rice; it’s shaped like a pine cone and has an infindibular stalk projecting from it....

Ovaries
2013-03-05 14:55:04

The ovaries are the two reproductive female organs where the eggs are produced. These are parallel to the testes in men. Formation and Orientation Each ovary is the size of an almond and is located on one side of the pelvis before the ureter and internal iliac artery but after the external iliac artery. They are attached to either side of the uterus. They are connected and release eggs to fallopian tubes, though not attached, monthly during the menstrual cycle. They also produce...

Hypothalamus
2013-03-04 13:43:30

The hypothalamus is an organ that serves as an important link, along the hypothalamic-hypophyseal axis, between the nervous system and the endocrine system. It is located within the cranial cavity, in the cerebrum, right below the thalamus. It also forms the floor of the third ventricle in the brain. It contains neural pathways, blood vessels, glial cells, and secretory cells—all of which work together to control things like body temperature, hunger, thirst, sleep, and hormonal and...

More Articles (8 articles) »
Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related